Drugs · Entity Annotation Prototype (beta)

9articles mentioning drugs

30drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: STAR0602 ×

STAR0602

This drug is selected. Its supporting articles are shown below.

STAR06029

Articles mentioning STAR0602

9 articles · page 1 of 1

169 Impact of a Vβ6/Vβ10 targeting IL-2 fusion protein (invikafusp alfa) on the peripheral immunome, including stimulation of memory T cells with self-renewing properties, in patients with cancer

jitc · abstract · 2025-11-04 · 10 matching annotations

95.1%

STAR0602 invikafusp alfa solid tumors START-001 human cancers

…levels, suggestive of a tumor response to treatment.Conclusions STAR0602 induces dynamic immune activation, promoting the potent and sel…

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression

jitc · abstract · 2026-07-01 · 3 matching annotations

97.4%

olaparib STAR0602 mSTAR1302 mSTAR1302-mediated Metastatic castration-resistant prostate cancer (mCRPC)mCRPC NCT05592626

…ate cancer.Methods The antitumor activity of the PARP inhibitor olaparib combined with mSTAR1302, the murine surrogate of STAR0602, was …

625 Docetaxel enhances the anti-tumor activity of a novel bi-functional TCR activating molecule in breast and prostate cancer models

jitc · abstract · 2025-11-04 · 3 matching annotations

93.5%

docetaxel docetaxel-induced STAR0602 mSTAR1302 4T1 TRAMP-C2

…AR1302 (1mg/kg) was administered once per week for 3 weeks, and docetaxel (500µg) in 3 doses, every other day, for 1 week. Tumors, spleen…

660 A novel TCRβ-directed IL-2 fusion molecule promotes memory CD8+ T cells with self-renewing properties in tumor ecosystems, further expanded by HDAC inhibition to elicit effective tumor suppression

jitc · abstract · 2025-11-04 · 3 matching annotations

95.5%

Entinostat STAR0602 mSTAR1302 solid malignancies human cancers CT26 EMT6

…-2R targeting to be significantly augmented by combination with Entinostat. These effects are associated with TCRVβ13/IL-2R targeting augm…

663 Epigenetic modulation synergizes with TCRβ-targeted IL-2 to yield CD8+ T cell dependent, MHC-I independent tumor control via an antibody associated mechanism

jitc · abstract · 2025-11-04 · 3 matching annotations

93.5%

Entinostat STAR0602 mSTAR1302 solid malignancies human cancers EMT6 MC38

….2/13.3, in combination with the class I HDAC inhibitor (HDACi) Entinostat, an epigenetic modulator that enhances tumor immune cell recogn…

916 A novel anti-TCR Vb targeted bispecific antibody in combination with a poly ADP-ribose polymerase inhibitor (PARPi) enhances anti-tumor immune response in prostate cancer models

jitc · abstract · 2025-11-04 · 3 matching annotations

96.0%

Olaparib STAR0602 mSTAR1302 IL-2 mCRPC prostate cancer NCT05592626 TRAMP-C2

…uppression of TRAMP-C2 and RM-1 tumors compared to mSTAR1302 or Olaparib monotherapies. In both models, combination therapy resulted in …

629 Triple combination therapy with a TCR Vb-directed bifunctional molecule, cisplatin and anti-PD-1 in immune checkpoint blockade-refractory head and neck murine tumor models

jitc · abstract · 2025-11-04 · 2 matching annotations

96.5%

STAR0602 mSTAR1302 cisplatin head and neck squamous cell carcinoma (HNSCC)NIH Intramural Animal Care and Use Committee carcinogen-associated HNSCC C57BL/6 mice

…sions These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recur…

Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models

jitc · abstract · 2025-10-28 · 2 matching annotations

96.4%

STAR0602 cisplatin mSTAR1302 head and neck squamous cell carcinoma (HNSCC)

…usion These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recur…

1316 Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1/2 trial

jitc · abstract · 2025-11-07 · 1 matching annotations

78.8%

Invikafusp alfa invikafusp STAR0602 colorectal cancer Memorial Sloan Kettering Cancer Center CEIm HM Hospitales FDA Dana Farber Cancer Institute TMB-H solid tumors TMB-H

…Background Invikafusp alfa (STAR0602), a selective, dual T cell agonist targeting Vβ6/10 T…

Browse drugs

STAR0602

Articles mentioning STAR0602